정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
128 | Recruiting | Treatment of Angiotensin Peptide (1-7) for COVID-19 | COVID-19 | Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma | Not Applicable | Kanuni Sultan Suleyman Training and Research Hospital | OTHER | 20 | All | 18 Years | Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey |
127 | Recruiting | Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs | COVID-19 Pneumonia | Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells Drug: Antibiotics Drug: Hormones Drug: Anticoagulant Therapy Device: Оxygen therapy |
Phase 2 | Institute of Cell Therapy, Kyiv City Clinical Hospital # 4 | INDUSTRY | 30 | All | 18 Years ~ 75 Years | Institute of Cell Therapy, Kyiv, Ukraine |
126 | Completed | Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells | Sars-CoV2 | Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells Other: Standard treatment according to the Clinical protocols |
Phase 2 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Belarusian State Medical University | OTHER_GOV | 32 | All | 18 Years ~ 70 Years | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus |
125 | Recruiting | Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study | NEBULIZATION | Drug: inhaled type I interferon Drug: WFI water nebulization |
Phase 2 | Centre Hospitalier Universitaire, Amiens | OTHER | 146 | All | 18 Years | CH d'Abbeville, Abbeville, France CHU Amiens, Amiens, France CH Compiegne-Noyon, Compiegne, France CH de l'Arrondissement de Montreuil-sur-mer, Rang-du-Fliers, France CH de Saint-Quentin, Saint-Quentin, France CH de Tourcoing, Tourcoing, France CH de valenciennes, Valenciennes, France |
124 | Completed | Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention | COVID-19 | Drug: Treatment and prophylaxis Other: Standard Public Health measures |
Phase 3 | Fundacion FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promocion de la Salud y la Ciencia, Germans Trias i Pujol Hospital, Department of Health, Generalitat de Catalunya, Laboratorios Gebro Pharma SA, Laboratorios Rubio, Institut Catala de Salut | OTHER | 2300 | All | 18 Years | Departament de Salut, Barcelona, Spain |
123 | Recruiting | Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells | Use of Stem Cells for COVID-19 Treatment | Biological: WJ-MSCs | Phase 1 | Stem Cells Arabia | OTHER | 5 | All | 18 Years | Stem Cells Arabia, Amman, Jordan |
122 | Completed | Treatment of COVID-19 Patients With Anti-interleukin Drugs | COVID-19 | Other: Usual Care Drug: Anakinra Drug: Siltuximab Drug: Tocilizumab |
Phase 3 | University Hospital, Ghent, Belgium Health Care Knowledge Centre | OTHER | 342 | All | 18 Years | AZ Sint-Jan Brugge, Brugge, Belgium University Hospital Saint-Pierre, Brussels, Belgium Erasmus University Hospital, Brussels, Belgium University Hospital Saint-Luc, Brussels, Belgium University Hospital Antwerp, Edegem, Belgium Ziekenhuis Oost-Limurg, Genk, Belgium AZ Sint-Lucas, Gent, Belgium University Hospital Ghent, Gent, Belgium Jessa ZH, Hasselt, Belgium University Hospital Brussels, Jette, Belgium CHU Tivoli, La Louviere, Belgium CHR de la Citadelle, Liege, Belgium University Hospital Liege, Liege, Belgium Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium AZ Delta, Roeselare, Belgium |